Veradigm Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Veradigm Inc. (MDRX) provides healthcare technology solutions, including electronic health records, practice management software and data analytics to providers, payers and life sciences companies in the United States and internationally. Founded in 1986 and headquartered in Chicago, Illinois, the company offers practice management software, AI patient scheduling software, electronic statements and payments, PayerPath clearinghouse; revenue cycle services and coding services; electronic health records solutions such as ePrescribe with EPCS, Veradigm EHR and Practice Fusion EHR; patient engagement platforms; API connectivity solutions including Veradigm Connect and Veradigm App Expo; risk adjustment solutions comprising health equity analytics, risk adjustment analytics, Risk Mitigator and comprehensive submissions; quality analytics and management; data exchange and coding solutions such as eChart Courier, eChart Coder and eChart integration; clinical data registries; provider engagement solutions; care gap alerting and gap closure services; real-world data solutions featuring NLP-enriched EHR data and real-world evidence analytics platform; and digital health media solutions. Veradigm serves ambulatory and specialty care settings, health plans, PBMs, insurance companies and biopharma markets through its Veradigm Network. The company, formerly Allscripts Healthcare Solutions, rebranded to Veradigm in January 2023; acquired revenue cycle management firm Koha Health in early 2024 to enhance ambulatory and musculoskeletal care capabilities; integrated former Pulse8, Babel Health and Evalytica solutions into its payer analytics and real-world evidence platforms; and in 2025 explores strategic alternatives including a potential sale process with initial bids collected.
Veradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update Transcript
Veradigm Files 2023 and 2024 Form 10-K
Veradigm Survey: Independent Practices Rely on Technology to Stay Independent
Veradigm Receives KLAS 2026 Points of Light Award for Embedding SDOH Data in Provider EHR Workflows
Veradigm Doubles India-Based Employee Footprint, Adds New Managing Director
Veradigm: You Can't Fall Off The Floor
Veradigm Appoints Christian Greyenbuhl as Chief Financial Officer
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
Veradigm Provides Business and Strategy Update
Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution
Veradigm to Release Business Update February 17th and Host Investor Call February 18th
Veradigm Extends Stockholder Rights Plan
Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent Practices
Veradigm (NASDAQ:MDRX) Shares Gap Up – What’s Next?
Veradigm Launches Enhanced Ambient Scribe Capabilities
Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer
Veradigm Inc. - Special Call
Veradigm Provides 2025 Business Update
DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of Veradigm LLC Customers Whose Data May Have Been Compromised
Veradigm: A Relisting Special Situation With Strategic Optionality